Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: risk reduction, management and possibilities for subsequent immunoregulation

Cover Page

Cite item

Full Text


The risk of progressive multifocal leukoencephalopathy (PML) is one of the factors limiting the widespread use of natalizumab (NTZ). As a strategy for potentially reducing the frequency of the NTZ-associated PML, while maintaining the high therapy efficacy, in addition to the widely-used risk stratification strategy based on anti-JC virus antibody index and therapy duration, we propose the administration of NTZ with an extended dosing interval. Opinions vary on the effectiveness of plasmapharesis in confirmed cases of PML. The most challenging problem is how to manage patients, who develop PML, and what MS disease-modifying therapy should be considered for the subsequent use.

About the authors

Natalia V. Khachanova

Pirogov Russian National Research Medical University

Author for correspondence.
Russian Federation, Moscow

Alexey N. Boyko

Pirogov Russian National Research Medical University; Federal Center for Cerebrovascular Pathology and Stroke

Russian Federation, Moscow

Maria V. Shumilina

City Clinical Hospital No. 31

Russian Federation, St. Petersburg

Inna V. Smagina

Altai State Medical University

Russian Federation, Barnaul

Nadezhda A. Malkova

Novosibirsk State Medical University; State Novosibirsk Regional Clinical Hospital

Russian Federation, Novosibirsk

Stella A. Sivertseva

Health Unit «Neftyanik»

Russian Federation, Tyumen

Ekaterina V. Popova

Pirogov Russian National Research Medical University; City Clinical Hospital No. 24

Russian Federation, Moscow

Timur I. Khaibullin

Republican Clinical Neurological Center

Russian Federation, Kazan


  1. Díaz C., Zarco L., Rivera D.M. Highly active multiple sclerosis: An update. Mult Scler Relat Disord 2019; 30: 215–224. doi: 10.1016/j.msard.2019.01.039. PMID: 30822617.
  2. Polman C.H., O’Connor P.W., Havrdova E. et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899–910. doi: 10.1056/NEJMoa044397. PMID: 16510744.
  3. Miller D., Soon D., Fernando K. et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007; 68 (17): 1390–401. doi: 10.1212/01.wnl.0000260064.77700.fd. PMID: 17452584.
  4. Bloomgren G., Richman S., Hotermans C. et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870–80. doi: 10.1056/NEJMoa1107829. PMID: 22591293.
  5. Berger J, Aksamit A, Clifford D et al. PML diagnostic criteria: Consensus statement from the AAN Neuroinfectious Disease Section. Neurology 2013; 80: 1430–1438. doi: 10.1212/WNL.0b013e31828c2fa1. PMID: 23568998.
  6. Wattjes MP, Richert ND, Killestein J, et al. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler 2013; 19: 1826–1840. doi: 10.1177/1352458513510224. PMID: 24192217.
  7. McGuigan C., Craner M., Guadagno J. et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry 2016; 87:117-125. doi: 10.1136/jnnp-2015-311100EMA. PMID: 28850992.
  8. European Medicines Agency. European Medicines Agency confirms recommendations to minimise risk of brain infection PML with Tysabri [Internet]. Available from:
  9. Khachanova N.V., Davydovskaya M.V., Evdoshenko E.P. Updated risk stratification and risk management plan for Natalizumab-associated progressive multifocal leukoencephalopathy. RMJ 2017; 13: 3–7. (In Russ.)
  10. Major E.O., Yousry T.A., Clifford D.B. Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned. Lancet Neurol 2018; 17: 467–480. doi: 10.1016/S1474-4422(18)30040-1. PMID: 29656742.
  11. Meira M., Sievers C., Hoffman F. et al. Natalizumab-induced POU2AF1/SpiB upregulation: a possible route for PML development. Neurol Neuroimmunol Neuroinflamm 2016; 3: e223. doi: 10.1212/NXI.0000000000000223. PMID: 27088119.
  12. Sørensen P., Bertolotto A., Edan G. et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012; 18: 143–152. doi: 10.1177/1352458511435105. PMID: 22312009.
  13. Ayzenberg I., Lukas C., Trampe N. et al. Value of MRI as a surrogate marker for PML in natalizumab long-term therapy. J Neurol 2012; 259: 1732–1733. doi: 10.1007/s00415-012-6426-5. PMID: 22289971.
  14. Scarpazza C., Signoi A., Cosottini M. et al. Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate. Mult Scler 2019: 1352458519854162. doi: 10.1177/1352458519854162. PMID: 31144589.
  15. Lindå H., von Heijne A. Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy. Front Neurol 2013; 4: 11. doi: 10.3389/fneur.2013.00011. PMID: 23423248.
  16. Scarpazza C., Signori A., Prosperini L. et al. Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution. J Neurol Neurosurg Psychiatry 2019; 90: 261–267. doi: 10.1136/jnnp-2018-319208. PMID: 30389778.
  17. Fabis-Pedrini M.J., Xu W., Burton J. et al. Asymptomatic progressive multifocal leukoencephalopathy during natalizumab therapy with treatment. J Clin Neurosci 2016; 25: 145–147. doi: 10.1016/j.jocn.2015.08.027. PMID: 26541323.
  18. McGovern E.M., Hennessy M.J. Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab. J Neurol 2013; 260: 665–667. doi: 10.1007/s00415-012-6759-0. PMID: 23212753.
  19. Prosperini L., Kinkel R.P., Miravalle A.A. et al. Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis. Ther Adv Neurol Disord 2019; 12: 1–17. doi: 10.1177/1756286419837809. PMID: 30956686.
  20. Fox R.J., Cree B.A., De Sèze J. et al. MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study. Neurology 2014; 82: 1491–1498. doi: 10.1212/WNL.0000000000000355. PMID: 24682966.
  21. Wipfler P., Harrer A., Pilz G. et al. Natalizumab saturation: Biomarker for individual treatment holiday after natalizumab withdrawal? Acta Neurol Scand 2014; 129: e12–e15. doi: 10.1111/ane.12182. PMID: 24032536.
  22. Rudick R.A., Sandrock A. Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother 2004; 4: 571–580. doi: 10.1586/14737175.4.4.571. PMID: 15853576.
  23. O’Connor P. Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis. Expert Opin Biol Ther 2007; 7: 123–136. doi: 10.1517/14712598.7.1.123. PMID: 17150024.
  24. Khatri B.O., Man S., Giovannoni G. et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 2009; 72: 402–409. doi: 10.1212/01.wnl.0000341766.59028.9d. PMID: 19188571.
  25. Rispens T., Vennegoor A., Wolbink G.J. et al. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped. Mult Scler 2012; 18: 899–901. doi: 10.1177/1352458511431073. PMID: 22183929.
  26. van Kempen Z.L., Leurs C.E., Witte B.I. et al. The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing. Mult Scler. 2018; 24: 805–810. doi: 10.1177/1352458517708464. PMID: 28485678.
  27. Vennegoor A., Rispens T., Strijbis E.M. et al. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult Scler 2013; 19: 593–600. doi: 10.1177/1352458512460604. PMID: 22992450.
  28. Zhovtis Ryerson L., Frohman T.C., Foley J. et al. Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry 2016; 87: 885–889. doi: 10.1136/jnnp-2015-312940. PMID: 26917698.
  29. Clerico M., De Mercanti S.F., Signori A. et al. Extending the interval of Natalizumab dosing: is efficacy preserved? Neurotherapeutics 2019. doi: 10.1007/s13311-019-00776-7. PMID: 31452081.
  30. Yamout B.I., Sahraian M.A., Ayoubi N.E. et al. Efficacy and safety of natalizumab extended interval dosing. Mult Scler Relat Disord 2018; 24: 113–116. doi: 10.1016/j.msard.2018.06.015. PMID: 29982107.
  31. Zhovtis Ryerson L., Foley J., Chang I. et al. Natalizumab extended interval dosing is associated with a reduction in progressive multifocal leukoencephalopathy (PML) risk in the TOUCH® Registry. J Neurol Neurosurg Psychiatry 2018; 89: No 6. Abstract A071.
  32. Alderazi Y., Campagnolo D., Bomprezzi R. Extended interval dosing of Natalizumab: a single center experience. Presented at: 63rd Annual Meeting of the American Academy of Neurology (AAN); Apr 9, 2011; Honolulu, HI; USA. Poster P 07200.
  33. Ciocanu D., Derache N., Berro M. et al. Long term extended interval dosing of Natalizumab does not change its clinico-radiological efficacy nor saturation capacity of CD49d: A real life study in a French MS center. Abstract P1201. Presented at: 2017 Congress of the European Committee For Treatment And Research In Multiple Sclerosis (ECTRIMS). Held Jointly With The 2017 Annual Meeting of the Americas Committee for Treatment and Research In Multiple Sclerosis (ACTRIMS); October 25-28, 2017, Paris, France.
  34. Bomprezzi R., Pawate S. Extended interval dosing of natalizumab: a two-center, 7-year experience. Ther Adv Neurol Disord 2014; 7: 227–231. doi: 10.1177/1756285614540224. PMID: 25342976.
  35. Richman S., Kappos L., Foley J. et al. Natalizumab-associated progressive multifocal leukoencephalopathy: survival and functional status of postmarketing cases. Presented at: 20th World Congress of Neurology (WCN); Nov 12, 2011; Marrakesh; Morocco. Poster 1432.
  36. Foley J.F., Goelz S., Hoyt T. et al. Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing. Mult Scler Relat Disord 2019; 31: 65–71. doi: 10.1016/j.msard.2019.03.017. PMID: 30939392.
  37. Pavlovic D., Patera A.C., Nyberg F. et al. Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disord 2015; 8: 255–273. doi: 10.1177/1756285615602832. PMID: 26600871.
  38. Chalkley J.J., Berger J.R. Progressive multifocal leukoencephalopathy in multiple sclerosis. Curr Neurol Neurosci Rep 2013; 13: 408. doi: 10.1007/s11910-013-0408-6. PMID: 24136456.
  39. Dong-Si T., Gheuens S., Gangadharan A. et al. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy. J Neurovirol 2015; 21: 637–644. doi: 10.1007/s13365-015-0316-4. PMID: 25771865.
  40. Clifford D.B. Progressive multifocal leukoencephalopathy therapy. J Neurovirol 2015; 21: 632–636. doi: 10.1007/s13365-014-0289-8. PMID: 25227934.
  41. Tan I.L., McArthur J.C., Clifford D.B. et al. Immune reconstitution inflammatory syndrome in natalizumab- associated PML. Neurology 2011; 77: 1061–1067. doi: 10.1212/WNL.0b013e31822e55e7. PMID: 21832229.
  42. Miller D.H., Khan O.A., Sheremata W.A. et al. A controlled trial of natalizumab for relapsing remitting multiple sclerosis. N Engl J Med 2003; 348: 15–23. doi: 10.1056/NEJMoa020696. PMID: 12510038.
  43. Landi D., Rossi N.D., Zagaglia S. et al. No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Neurology 2017; 88:1144–1152. doi: 10.1212/WNL.0000000000003740. PMID: 28228569.
  44. Tyler K.L., Vollmer T.L. To PLEX or not to PLEX in natalizumab-associated PML. Neurology 2017; 88: 1–2. doi: 10.1212/WNL.0000000000003747. PMID: 28228561.
  45. Scarpazza C., Prosperini L., De Rossi N. et al. To do or not to do? Plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy. Ann Neurol 2017; 82: 697–705. doi: 10.1002/ana.25070. PMID: 29023856.
  46. Stefoski D., Balabanov R., Waheed R. et al. Treatment of natalizumab-associated PML with filgrastim. Ann Clin Transl Neurol 2019; 6: 923–931. doi: 10.1002/acn3.776. PMID: 31139690.
  47. Cortese I., Muranski P., Enose-Akahata Y. et al. Pembrolizumab treatment for progressive multifocal leukoencephalopathy. N Engl J Med 2019; 380: 1597–1605. doi: 10.1056/NEJMoa1815039. PMID: 30969503.
  48. Dahlhaus S., Hoepner R., Chan A. et al. Disease course and outcome of 15 monocentrically treated natalizumab- associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry 2013; 84: 1068–1074. DOI: 10.1136/ jnnp-2013-304897. PMID: 23606731.
  49. Maillart E., Vidal J.S., Brassat D. et al. Natalizumab-PML survivors with subsequent MS treatment. Neurol Neuroimmunol Neuroinflamm 2017; 4: e346; doi: 10.1212/NXI.0000000000000346. PMID: 28616447.
  50. Maillart E., Louapre C., Lubetzki C., Papeix C. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option? Mult Scler 2014; 20: 505–509. doi: 10.1177/1352458513516530. PMID: 24367037.
  51. Heopner R., Faissner S., Ellrichmann G. et al. Rituximab postprogressive multifocal leukoencephalopathy: a feasible therapeutic option in selected cases. Ther Adv Neurol Disord 2014, 7: 289–291. doi: 10.1177/1756285614556287. PMID: 25371711.
  52. Mancinelli C.R., Scarpazza C., Santuccio G. et al. Dealing with highly active multiple sclerosis after natalizumab-associated PML: could rituximab be of help? Neurol Sci 2018; 39: 965–966. doi: 10.1007/s10072-017-3228-7. PMID: 29302813.

Supplementary files

Supplementary Files

Copyright (c) 2019 Khachanova N.V., Boyko A.N., Shumilina M.V., Смагина I.V., Malkova N.A., Sivertseva S.A., Popova E.V., Khaibullin T.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-83204 от 12.05.2022.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies